Masimo Corp (MASI) Files Form 4 Insider Selling : Paul Jansen Sells 20,000 Shares

Masimo Corp (MASI): Paul Jansen , EVP, Bus Dev of Masimo Corp sold 20,000 shares on May 24, 2016. The Insider selling transaction was reported by the company on May 26, 2016 to the Securities and Exchange Commission. The shares were sold at $48.88 per share for a total value of $977,600.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 6, 2016, Jon Coleman (Pres-WW Sales,Pro Svc,Med Affs) sold 8,000 shares at $47.00 per share price.On Apr 29, 2016, Paul Jansen (EVP, Bus Dev) sold 10,000 shares at $44.88 per share price.Also, On Mar 23, 2016, Yongsam Lee (EVP & CIO) sold 96,000 shares at $39.97 per share price.On Mar 17, 2016, Raad Mark De (EVP & Chief Financial Officer) sold 40,000 shares at $39.00 per share price.

Shares of Masimo Corporation (MASI) ended Wednesday, May 25, 2016 session in red amid volatile trading. The shares closed down -0.22 points or -0.44% at $49.35 with 3,41,120 shares getting traded. Post opening the session at $49.58, the shares hit an intraday low of $49.26 and an intraday high of $49.94 and the price vacillated in this range throughout the day. The company has a market cap of $2,417 M and the number of outstanding shares has been calculated to be 4,89,85,489 shares. The 52-week high of Masimo Corporation is $49.68 and the 52-week low is $33.03.

Masimo Corporation Money Flow Index Chart

Company has been under the radar of several Street Analysts.Masimo Corporation is Upgraded by Piper Jaffray to Overweight. Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on May 5, 2016.Masimo Corporation is Reiterated by Wedbush to Outperform and the brokerage firm has raised the Price Target to $ 57 from a previous price target of $51 .The Rating was issued on May 5, 2016.

Masimo Corporation is a global medical technology company that develops manufactures and markets non-invasive patient monitoring products. The Company’s core business is measure-through-motion and low-perfusion pulse oximetry monitoring known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include non-invasive optical blood constituent monitoring optical organ oximetry monitoring electrical brain function monitoring acoustic respiration monitoring and optical gas monitoring. In addition the Company offers Root patient monitoring and connectivity platform the Radical-7 bedside and portable patient monitor and the Radius-7 wearable wireless patient monitor. The Company also has the Patient SafetyNet remote patient surveillance monitoring system which allows up to 80 patients to be monitored simultaneously through a central station or remotely by care providers through their pagers or smart phones.

Leave a Reply

Masimo Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Masimo Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.